ClinicalTrials.gg
CompletedNCT04546347Updated Jan 20, 2021

A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833

A Phase 1 interventional study of [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL) and AZD9833 film-coated tablet A Dose 1 in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to female participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-20.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing AZD9833 in Breast Neoplasms — 6 open to participants now, 10 under way, 7 of them phase 3. AZD9833 · Breast Neoplasms.

Enrollment
13th of 17
32 · median 150
Started
2020
with 2 others
Phase 1
7 of 17
none open now
Registered
3rd of 17
by date
Lead sponsor
15 of 17
AstraZeneca

Among the 17 studies testing AZD9833 in Breast Neoplasms, this one is the 13th largest by enrollment, is one of 3 that started in 2020, is one of 7 in phase 1, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 17 studies testing AZD9833 in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About AZD9833

AZD9833: first FDA approval 2026 (ETCAMAH), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 50 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing AZD9833 in Breast Neoplasms, or all of them as a file.
02

Study summary

AstraZeneca AB is developing the test medicine, AZD9833, for the potential treatment of oestrogen receptor (ER) positive breast cancer. ER-positive breast cancer is where the cancer cells grow in response to the hormone oestrogen.

The study will try to identify and compare how much of the test medicine formulations (recipes) are taken up into the blood when given as a tablet, a solution and as an injection directly into the vein. The dose given directly into the vein will be radiolabelled, meaning that it contains a radioactive component in order to track where the drug is in the body.

This study will also look at the effect of food when taking the test medicine in the form of the tablet. The test medicine safety and tolerability will also be assessed.

This is a one-part study involving up to 32 healthy post-menopausal female volunteers aged 50 to 70. Volunteers will be randomly assigned to a group of up to 8, two groups will partake in four study periods and two groups will partake in three study periods. Volunteers will be admitted to the clinical unit on the day before dosing (Day -1) for each study period. On Day 1 of each study period, volunteers will receive either a single oral dose (tablet or solution) of AZD9833 or a single oral dose (tablet) of AZD9833 co-administered with a single radiolabelled IV dose of [14C]AZD9833, in either the fed or fasted state. There will be a minimum 7 day washout between periods.

Volunteers will remain resident until 72 hours post dose (Day 4) of each study period. A follow-up phone call will take place 5 to 7 days post-final dose to ensure the ongoing wellbeing of the volunteers.

Read the detailed description

The Sponsor is developing the test medicine, AZD9833, for the potential treatment of oestrogen receptor (ER) positive breast cancer. ER-positive breast cancer is where the cancer cells grow in response to the hormone oestrogen. The study will try to identify and compare how much of the test medicine formulations (recipes) are taken up into the blood when given as a tablet, a solution and as an injection directly into the vein. The dose given directly into the vein will be radiolabelled, meaning that it contains a radioactive component in order to track where the drug is in the body. This study will also look at the effect of food when taking the test medicine in the form of the tablet. The test medicine safety and tolerability will also be assessed. This is a one-part study involving up to 32 healthy post-menopausal female volunteers aged 50 to 70. Volunteers will be randomly assigned to a group of up to 8, two groups will partake in four study periods and two groups will partake in three study periods. Volunteers will be admitted to the clinical unit on the day before dosing (Day -1) for each study period. On Day 1 of each study period, volunteers will receive either a single oral dose (tablet or solution) of AZD9833 or a single oral dose (tablet) of AZD9833 co-administered with a single radiolabelled IV dose of [14C]AZD9833, in either the fed or fasted state. There will be a minimum 7 day washout between periods. Volunteers will remain resident until 72 hours post dose (Day 4) of each study period. A follow-up phone call will take place 5 to 7 days post-final dose to ensure the ongoing wellbeing of the volunteers.

03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • oestrogen receptor (ER) positive breast cancer
  • breast cancer
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy females, defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and FSH levels in the post menopausal range. Subjects taking prescribed medications are permitted on a case by case basis, as long as they have stable baseline conditions
  2. Between 50 and 70 years of age inclusive, at the time of signing
  3. (BMI) of 19.0 to 35.0 kg/m2 and minimum weight 50 kg and maximum weight 100 kg, as measured at screening
  4. Must be willing and able to communicate and participate in the whole study
  5. Must provide written informed consent

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
  2. Evidence of current SARS-CoV-2 infection
  3. History of or ongoing clinically significant visual disturbances including but not limited to visual hallucinations, migraine with visual symptoms, blurred vision, frequent floaters/flashes associated with other symptoms such as dizziness
  4. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of the IMP
  5. Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results, as judged by the investigator.
  6. Any clinically significant abnormal findings in vital signs at screening or pre dose, as judged by the investigator. Subjects with screening or pre-dose (Period 1 only) resting mean vital signs measurements (mean of three measurements separated by at least 2 min each) systolic BP \<100 mmHg, diastolic BP \<50 mmHg or heart rate \<50 bpm. Vital signs outside these limits can be repeated once in triplicate.
  7. Any clinically significant abnormalities at screening or pre-dose on 12-lead as judged by the investigator, including non-sinus rhythms, PR interval \<120 msec or >220 msec, ventricular rate \<50/min or >100/min, QRS interval >120 msec, or >450 msec. ECGs can be repeated once if parameters are outside these limits for confirmation
  8. Any positive result on screening for serum surface antigen (HBsAg), antibody, (HCV Ab) and (HIV) antibody.
  9. Known or suspected history of drug abuse within the past 2 years, as judged by the investigator
  10. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion ends 3 months after the final dose or 1 month after the last visit whichever is the longest. Note: subjects consented and screened, but not administered IMP in this study or a previous Phase 1 study, are not excluded.
  11. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening
  12. Subjects with history of significant allergy/, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9833 or the formulation . Hay fever is allowed unless it is active.
  13. Current smokers or those who have smoked or used nicotine products within the previous 12 months, as verified by a urine cotinine test at screening or admission.
  14. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months.
  15. Positive screen for drugs of abuse at screening or admission to the clinical unit or positive screen for alcohol at screening or admission to the clinical unit.
  16. Known or suspected history of alcohol abuse or excessive intake of alcohol >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
  17. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator.
  18. Subjects with a history of cholecystectomy or gall stones.
  19. Any relevant history of QT prolongation (including previous studies) or known risk factors for this (eg hypokalaemia, hypomagnesemia or recent use of medicines which can prolong QTcF).
  20. Excessive intake of caffeine-containing drinks or food (eg coffee, tea, chocolate) as judged by the investigator. Excessive intake of caffeine defined as the regular consumption of more than 600 mg of caffeine per day (eg >5 cups of coffee) or would likely be unable to refrain from the use of caffeine-containing beverages during confinement at the site.
  21. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks or drugs known to be associated with increased risk of QT prolongation within 4 weeks prior to the first administration of IMP.
  22. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of investigational product or longer if the medication has a long half life except up to 4 g of paracetamol per day and those deemed necessary by the investigator to treat AEs. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the investigator.
  23. Must agree to not use warfarin or phenytoin (and other coumarin-derived vitamin K antagonist anticoagulants) for 2 weeks after last administration of investigational product.
  24. Subjects who are, or are immediate family members of, a study site or sponsor employee.
  25. Subjects who have previously received AZD9833.
  26. Use of systemic oestrogen-containing hormone replacement therapy within 6 months prior to first dose in the study.
  27. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (ie during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements; subjects who have had fever, sore throat or flu like symptoms in the 2 weeks prior to IMP administration.
  28. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.
  29. Subjects who have been administered an IMP in a [14C] absorption, distribution, metabolism and elimination study in the last 12 months
  30. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
  31. Vulnerable subjects, eg kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  32. Failure to satisfy the investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    14CAZD9833 Infusion NMT 22.8 kBq/5mL

    Dose 1 14CAZD9833 Solution for Infusion

    Radiation: [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)

  • Experimental
    AZD9833 film-coated tablet A Dose 1

    Dose 1 AZD9833 film-coated tablet type A

    Drug: AZD9833 film-coated tablet A Dose 1

  • Experimental
    AZD9833 Oral Solution

    Dose 1 AZD9833 oral solution

    Drug: AZD9833 Oral Solution

  • Experimental
    AZD9833 film-coated tablet B Dose 1

    Dose 1 AZD9833 film-coated tablet type B

    Drug: AZD9833 film-coated tablet B Dose 1

  • Experimental
    AZD9833 film-coated tablet A Dose 2

    Dose 2 AZD9833 film-coated tablet type A

    Drug: AZD9833 film-coated tablet A Dose 2

  • Experimental
    AZD9833 film-coated tablet B Dose 2

    Dose 2 AZD9833 film-coated tablet type B

    Drug: AZD9833 film-coated tablet B Dose 2

Interventions

06

What researchers measure

Primary outcomes

  1. Relative bioavailability of AZD9833 based on Area under the curve from time 0 to the time of last measurable concentration (AUC0-t)

    Assessment of the PK (pharmacokinetics) on AZD9833 by measuring relative bioavailability based on AUC0-t

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose

  2. Relative bioavailability of AZD9833 based on area under the concentration time curve from time zero to the last quantifiable concentration (AUC0-inf)

    Assessment of the PK (pharmacokinetics) on AZD9833 by measuring relative bioavailability based on AUC0-inf

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose

  3. Relative bioavailability of AZD9833 based on Maximum observed concentration (Cmax)

    Assessment of the PK (pharmacokinetics) on AZD9833 by measuring relative bioavailability based on Cmax

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose

Secondary outcomes

  1. Area under the concentration time curve from time zero to the last quantifiable concentration (AUC0-inf) for AZD9833 vs [14C]-AZD9833 and total radioactivity

    Assessment of AZD9833 and total radioactivity by measuring the concentration time curve from time zero to the last quantifiable concentration (AUC0-inf)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose

  2. Number of adverse events (AE) experienced by subjects

    Safety and tolerability assessed through the incidence of AEs

    Time frame: AEs recorded from the time of informed consent until discharge from the study (72 hours post-dose)

Other outcomes

  1. Evaluation on exposure differences between and including both dose levels of AZD9833

    Results from exposure-dose analysis on exposure differences between and including both doses

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jan 2021, 3 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 3 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2020
First posted
Sep 14, 2020
StartActual
Sep 17, 2020
Primary completionActual
Jan 7, 2021
CompletionActual
Jan 7, 2021
Last update
Jan 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04546347
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Sep 14, 2020
Start date
Sep 17, 2020
Primary completion
Jan 7, 2021
Completion
Jan 7, 2021
Last update
Jan 20, 2021

Study contacts

Somasekhara Menakuru, MBBS MS MRCS
principal investigator · Quotient Sciences Limited (indemnified by Medical Protection Society)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9833

Start the discussion